Navegando por Palavras-chave "Postmenopause,"

Agora exibindo 1 - 1 de 1
  • Imagem de Miniatura
    Item
    Acesso aberto (Open Access)
    Ação da terapia hormonal na Esclerose Lateral Amiotrófica: revisão sistemática
    (Universidade Federal de São Paulo (UNIFESP), 2019-12-18) Vasconcelos, Katia De [UNIFESP]; Simoes, Manuel De Jesus [UNIFESP]; Oliveira, Acary Souza Bulle [UNIFESP]; Fuchs, Luiz Fernando Portugal [UNIFESP]; Girão, Manoel João Batista Castello [UNIFESP]; http://lattes.cnpq.br/3911841387107665; http://lattes.cnpq.br/0822381310382371; http://lattes.cnpq.br/0973903299568770; http://lattes.cnpq.br/5987164343458678; Universidade Federal de São Paulo (UNIFESP)
    Amyotrophic Lateral Sclerosis (ALS), a fatal disease characterized by muscle and fasciculations weakness and atrophy and decreased reflexes due to upper and lower motor neurons death. It can be present in both sexes (55-65 years), but with predominance in males. However, in female patients, ALS presents its first symptoms when they are already postmenopausal, when then the incidence ratio of the disease is practically equal between the sexes. Which leads to a probable involvement of sex hormones in the development and protection against ALS. The aim of this systematic review, which used the PRISMA consensus and NOS (New Casttle-Ottawa Scale) score, was to evaluate the evidence of the action of hormone therapy in women with ALS. The Medline and Cochrane databases were accessed from March 2019 to June 2019, and only full text articles in Spanish, English and Portuguese languages were included. Only four articles matched our inclusion criteria. Postmenopausal women who used exogenous estrogen did not have the same protective factor as women still under the action of endogenous estrogen in the same age group. There was also no increase in survival of these women.